Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 18/20 | 0.59 |
| ▸ | NPY1R | P25929 | 11/20 | 0.59 |
| ▸ | NPY5R | Q15761 | 10/20 | 0.59 |
| ▸ | NPY2R | P49146 | 7/20 | 0.59 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL30763300 | 0.92 | NPY4R (0.61) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30087525 | 0.92 | NOD1 (0.50) | NPY4RNPY1RNPY5RNPY2RNOD1 | |
| SCHEMBL30472837 | 0.92 | NOD1 (0.50) | NPY4RNPY1RNPY5RNPY2RNOD1 | |
| SCHEMBL29947151 | 0.91 | NPY4R (0.70) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29947137 | 0.91 | NPY4R (0.70) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30400285 | 0.91 | NPY4R (0.53) | NPY4RNPY1RNPY5RNPY2RNOD1 | |
| SCHEMBL27852306 | 0.90 | NPY4R (0.57) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL27852310 | 0.90 | NPY4R (0.57) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30611010 | 0.90 | NPY4R (0.55) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30974000 | 0.89 | NPY4R (0.53) | NPY4RNPY1RNPY5RNPY2RNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497644-B2 | Subtilisin variants and their use | Fresenius Kabi Ipsum S.R.L. (IT) | 2025-12-16 | — | — | US | disclosed |
| EP-4638730-A1 | THERMOSTABLE SUBTILISIN VARIANTS AND THEIR USE | Fresenius Kabi iPSUM S.r.l. (IT) | 2025-10-29 | — | — | EP | disclosed |
| US-20240360179-A1 | STAPLED PEPTIDES AND METHODS THEREOF | PARABILIS MEDICINES, INC. | 2024-10-31 | — | — | US | disclosed |
| WO-2024133313-A1 | THERMOSTABLE SUBTILISIN VARIANTS AND THEIR USE | ENZYPEP B.V. (NL) | 2024-06-27 | — | — | WO | disclosed |
| US-20240043897-A1 | SUBTILISIN VARIANTS AND THEIR USE | Fresenius Kabi Ipsum S.R.L. (IT) | 2024-02-08 | — | — | US | disclosed |
| EP-4291647-A1 | SUBTILISIN VARIANTS AND THEIR USE | Fresenius Kabi iPSUM S.r.l. (IT) | 2023-12-20 | — | — | EP | disclosed |
| WO-2022171667-A1 | SUBTILISIN VARIANTS AND THEIR USE | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360179-A1 | STAPLED PEPTIDES AND METHODS THEREOF | CTNNB1, APC, CTNNA1 | NPY4R 599/4885NPY1R 352/4885NPY5R 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.